Deutetrabenazine

Chemical formula: C₁₉H₂₇NO₃  Molecular mass: 323.466 g/mol  PubChem compound: 73442840

Active ingredient description

Deutetrabenazine and the major circulating metabolites are reversible inhibitors of VMAT2, resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores in dopaminergic regions (e.g. striatum and cortex) of the brain. While the precise mechanism of action by which deutetrabenazine exerts its effects in the treatment of tardive dyskinesia is unknown, it is believed to be related to its effect as a depletor of monoamines from nerve terminals.

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Document Type Information Source  
 AUSTEDO Prolonged-release tablet MPI, EU: SmPC European Medicines Agency (EU)
 AUSTEDO Coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 1392826-25-3
DrugBank Drug: DB12161
PubChem Compound: 73442840
RxNorm Ingredient: 1876905
SNOMED-CT Concept: 733658007
Deutetrabenazine (substance)
UNII Identifier: P341G6W9NB
DEUTETRABENAZINE

Medicines

Deutetrabenazine is an active ingredient of these brands:

Estonia (EE)

Israel (IL)

Lithuania (LT)

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈